Success Metrics

Clinical Success Rate

100.0%

Based on 3 completed trials

Completion Rate

100%(3/3)

Active Trials

0(0%)

Results Posted

0%(0 trials)

Phase Distribution

Ph phase_1

67%

Ph phase_2

33%

Phase Distribution

Early Stage

Mid Stage

Late Stage

Phase Distribution3 total trials

Phase 1Safety & dosage

2(66.7%)

Phase 2Efficacy & side effects

1(33.3%)

Highest Phase Reached

Phase 2

Trial Status & Enrollment

Completion Rate

100.0%

3 of 3 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

trials recruiting

Total Trials

all time

Status Distribution

Completed(3)

Detailed Status

Completed3

Development Timeline

Analytics

Development Status

Total Trials

Active

Success Rate

100.0%

Most Advanced

Phase 2

Trials by Phase

Phase 12 (66.7%)

Phase 21 (33.3%)

Trials by Status

completed3100%

Recent Activity

0 active trials

Showing 3 of 3

completedphase_1

GSK1521498 Alcohol Interaction Study

NCT01366573

completedphase_1

To Evaluate the Influence of the A118G Polymorphism in the mu Opioid Receptor Gene (OPRM1) on Effects of GSK1521498 and Naltrexone on Physiological and Behavioural Markers of Brain Function in Healthy Social Drinkers

NCT01738867

completedphase_2

A 35 Day Study to Investigate the Effects of GSK1521498 on Bodyweight in Obese Subjects With Over-Eating Behaviours.

NCT01195792

Clinical Trials (3)

Showing 3 of 3 trials

NCT01366573Phase 1

GSK1521498 Alcohol Interaction Study

Completed

NCT01738867Phase 1

To Evaluate the Influence of the A118G Polymorphism in the mu Opioid Receptor Gene (OPRM1) on Effects of GSK1521498 and Naltrexone on Physiological and Behavioural Markers of Brain Function in Healthy Social Drinkers

Completed

NCT01195792Phase 2

A 35 Day Study to Investigate the Effects of GSK1521498 on Bodyweight in Obese Subjects With Over-Eating Behaviours.

Completed

All 3 trials loaded

Drug Details

Intervention Type: DRUG
Total Trials: 3